Trend Psychedelic developers converge on FDA approval as the main route to scale

Summary

GWI's Psychedelics and Healing Initiative reports that most practitioners and investors in the field now treat FDA-approved, regulated and insurance-reimbursable medicines as the best route to mass access. The Initiative frames regulatory integration, rather than decriminalization or informal clinic delivery, as the field's dominant strategy for 2026.